Ochsner Health, a healthcare provider in the U.S. Gulf South, has been named one of six new study sites by the Global Parkinson’s Genetics Program (GP2), which is studying the genetic basis of Parkinson’s disease among underrepresented populations. Increased genetic knowledge of these populations may support the…
Angels on Call, a home care services provider, has been granted Certified Parkinson Disease Care (CPDC) accreditation by the Parkinson’s and Movement Disorders Alliance (PMD Alliance). The agency became the first in its field to earn the certification in the U.S. The accreditation involves training staff to…
While loss of dopamine is a hallmark of Parkinson’s disease, patients with tremor may actually have pools of dopamine in a specific region of the brain, a study by researchers at Champalimaud Foundation in Portugal found. The results could pave the way for targeted treatments to control shaking at…
Mice modeling Parkinson’s disease performed better on tests of memory and spatial recognition when given daily under-the-skin injections of PNA5, an experimental ProNeurogen therapy targeting cognitive symptoms — suggesting the treatment’s potential to slow cognitive decline in patients. In this preclinical study, researchers from the University of Arizona…
An upcoming Phase 2 clinical trial is due to test NEU-411, a brain-penetrant oral small molecule that Neuron23 is developing to slow the progression of Parkinson’s in people with early-stage disease who carry variations in the LRRK2 gene. The trial, called NEULARK (NCT06680830), is expected to…
CND Life Sciences has been awarded a $4.2 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) toward a study that will evaluate the use of an alpha-synuclein skin test to aid in diagnosing Parkinson’s disease and tracking its progression. The Syn-Q clinical trial…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) recognized a Texas scientist for his contributions to Parkinson’s research and his commitment to mentoring the next generation of Parkinson’s scientists. Claudio Soto, PhD, a professor of neurology and director of the George and Cynthia Mitchell Center for Alzheimer’s…
For a 69-year-old man with advanced Parkinson’s disease, sleeping with the head of his bed elevated helped to decrease dizziness related to a sudden drop in blood pressure when he got up in the morning, according to a case reported in the Netherlands. This drop in blood pressure is…
A Phase 3 clinical trial evaluating investigational oral therapy solengepras as a treatment for Parkinson’s disease has dosed its first patient. The ARISE trial (NCT06553027) is evaluating the efficacy of solengepras as a potential add-on therapy to levodopa and other Parkinson’s medications. Patient recruitment is ongoing…
Deep brain stimulation (DBS) directed at the central part of the subthalamic nucleus (STN), a brain region important for movement, was the best option to improve balance and gait, including freezing of gait, in Parkinson’s disease, a small clinical trial suggests. Targeting the central STN with electrical stimulation…
Get regular updates to your inbox.